Topic overview
In brief
- Fidji Simo founded ChronicleBio to address chronic diseases like POTS, which she personally suffers from.
- The company aims to enhance clinical trials by grouping patients with similar symptoms for more effective drug testing.
- ChronicleBio has conducted 890 blood draws from 709 patients in multiple states and countries, offering free reports to participants.
Summary
In recent months, Fidji Simo has embarked on a significant venture by founding ChronicleBio, a company dedicated to addressing chronic diseases, particularly those that predominantly affect women, such as Postural Orthostatic Tachycardia Syndrome (POTS). Simo, who has been personally affected by POTS, has expressed that her health is at its worst, yet she remains committed to this important work. ChronicleBio aims to improve clinical trials by identifying and grouping patients with similar symptoms, which is crucial for developing effective treatments for these complex conditions.
The company recognizes that many chronic diseases, including POTS, often have various sub-diseases with different genetic causes contributing to similar symptoms. This complexity poses challenges for clinical trials, as a drug that may be effective for one subgroup might not work for others, leading to trial cancellations. To combat this issue, ChronicleBio is focused on finding patients with comparable symptoms and testing drugs on these specific subgroups, thereby increasing the likelihood of successful outcomes in clinical trials.